GeneQuantum Secures $13 Billion Deals with Biohaven and AimedBio for ADC Development
Suzhou based biotech firm GeneQuantum has announced a series of major commercial cooperation pacts worth...
GeneQuantum Healthcare
GeneQuantum Healthcare’s GQ1011 (AMB302) Receives FDA Approval for Clinical Study
China-based GeneQuantum Healthcare, a leading developer of antibody drug conjugates (ADCs), has announced that it...
GeneQuantum Healthcare’s GQ1005 ADC Receives CDE Clearance for Phase III Breast Cancer Trial
SUZHOU—GeneQuantum Healthcare (Suzhou) Co., Ltd has received clearance from the Center for Drug Evaluation (CDE)...
GeneQuantum Appoints Dr. Lingyu Zhu as Chief Business Strategy and Development Officer
SUZHOU—GeneQuantum, a leading player in the biotech industry known for its cutting-edge enzymatic site-specific conjugation...
Nona Biosciences Partners with GeneQuantum Healthcare to Advance Drug Conjugate Discovery
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the...
InxMed Partners with GeneQuantum Healthcare to Develop Innovative ADCs
China-based firm InxMed (Nanjing) Co., Ltd has announced a strategic partnership with compatriot firm GeneQuantum...
GeneQuantum Healthcare and Aimed Bio Expand Partnership to Develop Five Novel ADC Drugs
China-based GeneQuantum Healthcare has unveiled a new agreement to expand its existing partnership with South...
WuXi XDC Partners with GeneQuantum for ADC Development
China-based WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a...